Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Immune Checkpoint Inhibition for the Treatment of Cancers: An Update and Critical Review of Ongoing Clinical Trials Publisher Pubmed



Akhbariyoon H1 ; Azizpour Y1 ; Esfahani MF1 ; Firoozabad MSM3 ; Rad MR2 ; Esfahani KS3 ; Khoshavi N3 ; Karimi N3 ; Shirinisaz A3 ; Abedi F3 ; Rad MR2 ; Sharifi P3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biochemistry, Tarbiat Modares University, Tehran, 14115-175, Iran
  2. 2. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Biology, Faculty of Science, Yazd University, Yazd, Iran

Source: Clinical Immunology Published:2021


Abstract

Advances in Cancer immunotherapy in the past few years include the development of medications that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death protein 1 (PD1), and programmed cell death ligand 1 (PD-L1) are three co-inhibitory receptors that are expressed in the tumor microenvironment. Immune checkpoint inhibitors (ICI) that target these biomarkers unleash the properties of effector T cells that are licensed to kill cancer cells. Immune checkpoint blockade has dramatically changed the treatment landscape of many cancers. In this Review, we describe the current data regarding clinical trials of ICIs in six important cancers, including hepatocellular carcinoma (HCC), renal cell cancer (RCC), hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), non-small cell lung cancer (NSCLC), and head and neck cancer carcinoma (HNSCC). © 2021 Elsevier Inc.
Related Docs
View other Related Docs
1. Nivolumab Plus Ipilimumab Combination Therapy in Cancer: Current Evidence to Date, International Immunopharmacology (2023)
2. Immunologic Tumor Microenvironment Modulators for Turning Cold Tumors Hot, Cancer Communications (2024)
3. Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy, International Immunopharmacology (2022)
4. Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination With Checkpoint Inhibitors and Beyond, Current Drug Targets (2022)
5. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review, Current Cancer Therapy Reviews (2024)
6. Comparison of Laboratory Methods for the Clinical Follow up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead, Frontiers in Oncology (2022)
7. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
8. Research Paper: Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Basic and Clinical Neuroscience (2020)
Experts (# of related papers)
View all Related Experts
Mazdak Ganjalikhani Hakemi (9)
Marzieh Rezaei (5)
Other Related Docs
9. The Role of Tim-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?, Frontiers in Oncology (2020)
10. Tumour Immune Microenvironment in Primary and Metastatic Papillary Renal Cell Carcinoma, Histopathology (2020)
11. Engaging Stemness Improves Cancer Immunotherapy, Cancer Letters (2023)
12. Immunotherapies Targeting Tumor Vasculature: Challenges and Opportunities, Frontiers in Immunology (2023)
13. Targeting Immune Checkpoints: How to Use Natural Killer Cells for Fighting Against Solid Tumors, Cancer Communications (2023)
14. Immune Checkpoint Inhibitors As Mediators for Immunosuppression by Cancer-Associated Fibroblasts: A Comprehensive Review, Frontiers in Immunology (2022)
15. Producing Soluble Human Programmed Cell Death Protein-1: A Natural Supporter for Cd4+T Cell Cytotoxicity and Tumor Cells Apoptosis, Iranian Journal of Biotechnology (2019)
16. Construction and Periplasmic Expression of a Bispecific Tandem Scfv for Dual Targeting of Immune Checkpoints, Advanced Biomedical Research (2023)
17. An in Silico Investigation on the Binding Site Preference of Pd-1 and Pd-L1 for Designing Antibodies for Targeted Cancer Therapy, PLoS ONE (2024)
18. Insulin-Like Growth Factor Binding Protein 3 Chemosensitizes Pancreatic Ductal Adenocarcinoma Through Its Death Receptor, Pancreatology (2020)
19. Cancer Vaccines As a Targeted Immunotherapy Approach for Breast Cancer: An Update of Clinical Evidence, Expert Review of Vaccines (2022)
20. Identification of B and T Cell Epitope Based Peptide Vaccine From Igf-1 Receptor in Breast Cancer, Journal of Molecular Graphics and Modelling (2017)
21. Mrna-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients, Vaccines (2021)
22. Myeloid-Derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-Based Vaccine Function and Improved Immunity in Tumor Mice, Iranian Journal of Allergy, Asthma and Immunology (2018)
23. Immune Checkpoint Status and Tumor Microenvironment in Vulvar Squamous Cell Carcinoma, Virchows Archiv (2020)
24. Investigating the Dynamic Interplay Between Cellular Immunity and Tumor Cells in the Fight Against Cancer: An Updated Comprehensive Review, Iranian Journal of Blood and Cancer (2024)
25. Advances in Natural Killer Cell Therapies for Breast Cancer, Immunology and Cell Biology (2023)
26. Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities, Current Cancer Drug Targets (2022)
27. In Vitro Selective Depletion of Cd4+Cd25+ Regulatory T-Cells From Pbmc Using Anti-Tac-Sap, Journal of Immunotoxicology (2012)
28. Immune Evader Cancer Stem Cells Direct the Perspective Approaches to Cancer Immunotherapy, Stem Cell Research and Therapy (2022)
29. Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-Leukemia/Lymphoma Immune Therapy, Frontiers in Oncology (2022)
30. Enhanced in Vivo Anti-Tumor Efficacy of Whole Tumor Lysate in Combination With Whole Tumor Cell-Specific Polyclonal Antibody, Research in Pharmaceutical Sciences (2023)
31. The Nexus of Natural Killer Cells and Melanoma Tumor Microenvironment: Crosstalk, Chemotherapeutic Potential, and Innovative Nk Cell-Based Therapeutic Strategies, Cancer Cell International (2023)
32. Pd-1/Pd-L1 Interaction Regulates Bcl2, Ki67, Bax, and Casp3, Altering Proliferation, Survival, and Apoptosis in Acute Myeloid Leukemia, Iranian Journal of Allergy, Asthma and Immunology (2023)
33. Don't Eat Me/Eat Me Signals As a Novel Strategy in Cancer Immunotherapy, Heliyon (2023)
34. Immunogenic Cell Death Inducer Peptides: A New Approach for Cancer Therapy, Current Status and Future Perspectives, Biomedicine and Pharmacotherapy (2023)
35. A Novel Car Expressing Nk Cell Targeting Cd25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers, Frontiers in Oncology (2021)
36. Cxcl-10: A New Candidate for Melanoma Therapy?, Cellular Oncology (2020)
37. Regulating the Regulatory T Cells As Cell Therapies in Autoimmunity and Cancer, Frontiers in Medicine (2023)
38. Exploring the Cancer-Testis Antigen Boris to Design a Novel Multi-Epitope Vaccine Against Breast Cancer Based on Immunoinformatics Approaches, Journal of Biomolecular Structure and Dynamics (2022)
39. The Role of Immune Regulatory Molecules in Covid-19, Viral Immunology (2022)
40. Tim3 and Pd-1 As a Therapeutic and Prognostic Targets in Colorectal Cancer: Relationship With Sidedness, Clinicopathological Parameters, and Survival, Frontiers in Oncology (2023)
41. A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis, Current Therapeutic Research - Clinical and Experimental (2024)
42. In Silico Analysis of Transmembrane Protein 31 (Tmem31)Antigen to Design Novel Multiepitope Peptide and Dna Cancer Vaccines Against Melanoma, Molecular Immunology (2019)
43. The Molecular Perspective on the Melanoma and Genome Engineering of T-Cells in Targeting Therapy, Environmental Research (2023)
44. The Relationship Between Programmed Cell Death Receptor-1 Expression in Colon Tumoral Tissue and Clinical and Pathological Characteristics of Patients With Colon Cancer; [ارتباط بیان گیرنده ی مرگ برنامه ریزی شده 1 در بافت تومورال روده ی بزرگ با ویژگی های بالینی و آسیب شناسی بیماران مبتلا به سرطان روده ی بزرگ], Journal of Isfahan Medical School (2023)